Ahn, Myung Ju95 Appointment
Professor, Department of Hematology & Oncology, Samsung Medical Center
Hanyang University College of Medicine
|Fellowship||Asan Medical Center|
|Residency||Hanyang University Hospital|
|Internship||Hanyang University Hospital|
Master: Hanyang University Graduate School
Ph.D: Hanyang University Graduate School
Postdoctoral fellowship: Memorial Sloan Kettering Cancer Center, USA
Participation in Academic Societies
Member, Korean Medical Association
Member, Korean Association of Internal Medicine
Member, Korean Association of Oncology
Member, Korean Association for Cancer Research
Member, American Society of Oncology
Member, International Association Society of Lung Cancer
Member, European Society of Medical Oncology
Member, Korean Association of Clinical Oncology
Member, Korean Association Society of Lung Cancer
Member, Korean Head and Neck Cancer Society
J Clin Oncol. 2017 Apr 20;35(12):1288-1296. doi: 10.1200/JCO.2016.70.3223. Epub 2017 Feb 21.
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component
Expert Opin Drug Saf. 2017 Apr;16(4):465-469. doi: 10.1080/14740338.2017.1300656. Epub 2017 Mar 8.
EGFR TKI combination with immunotherapy in non-small cell lung cancer
Ann Oncol. 2017 Apr 1;28(4):874-881. doi: 10.1093/annonc/mdx008.
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9.
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Support Care Cancer. 2017 Mar;25(3):801-809. doi: 10.1007/s00520-016-3463-0. Epub 2016 Nov 8.
Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types